Biomea Fusion, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BMEA research report →
Range $10 – $40
Price Chart
About the company
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments.
- CEO
- Michael J. Hitchcock
- IPO
- 2021
- Employees
- 40
- HQ
- San Carlos, CA, US
Get TickerSpark's AI analysis on BMEA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $98.33M
- P/E
- -2.74
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 8.11
- EV/EBITDA
- -1.88
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -171.19%
- ROIC
- -212.95%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,409,000+0.0%
- Op Income
- $-81,307,000
- Net Income
- $-61,797,000+55.4%
- EPS
- $-1.18+69.2%
- OCF Growth
- +41.3%
- FCF Growth
- +41.5%
- 52W High
- $2.99
- 52W Low
- $0.87
- 50D MA
- $1.27
- 200D MA
- $1.35
- Beta
- -0.30
- RSI (14)
- 60
- Avg Volume
- 806.86K
No earnings-call transcripts are available for BMEA yet.
- Free Float
- 93.2%
- Shares Outstanding
- 72.30M
- Float Shares
- 67.41M
of shares held by institutions
66 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 2.97M | ▲ 797.98K |
| Two Sigma Advisers, LP | 105.80K | ▼ 160.90K |
| Point72 Asia (Singapore) Pte. Ltd. | 10.03K | ▼ 10.03K |
| Cubist Systematic Strategies, LLC | 3.37K | ▲ 2.52K |
| Quest Partners LLC | 3.31K | 0 |
| Comerica Bank | 20 | 0 |
Held by 24 ETFs
Biggest fund positions in BMEA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 10, 26 | Faust Elizabeth | other | 196,299 |
| Jun 10, 26 | AGUIAR ERIC | other | 196,299 |
| Jun 10, 26 | Ray Sumita | other | 196,299 |
| Jun 10, 26 | Averill Julianne | other | 173,711 |
| Apr 1, 26 | Erdtmann Rainer M | other | 452,512 |
| Apr 1, 26 | Hitchcock Michael J.M. | other | 667,477 |
| Dec 31, 25 | Erdtmann Rainer M | other | 0 |
| Dec 31, 25 | Erdtmann Rainer M | other | 0 |
| Dec 11, 25 | Erdtmann Rainer M | buy | 30,000 |
| Dec 2, 25 | Hitchcock Michael J.M. | buy | 100,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BMEA coverage
Recent articles, reports, and earnings notes.
No research on BMEA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BMEA report →Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
globenewswire.com · Aug 13
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
globenewswire.com · Aug 5
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
globenewswire.com · Jun 5
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
globenewswire.com · Jun 5
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
globenewswire.com · Jun 3
Biomea Fusion to Participate at Upcoming Investor Conferences
globenewswire.com · May 12
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
globenewswire.com · May 11
Biomea Fusion, Inc. (BMEA) Discusses Developments in Diabetes With Emphasis on Icovamenib and Clinical Trial Insights Transcript
seekingalpha.com · May 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.